Cancer-Associated Thrombosis

Abstract

Thrombosis is a common complication in patients with cancer and it is estimated that about 20% of patients with cancer experience venous thromboembolism (VTE). This complication is associated with high rate of morbidity and mortality and is sometimes the first manifestation of an occult cancer. The risk profiles and markers involved in cancerassociated thrombosis share similarities with inflammation-induced atherosclerosis and thrombosis. The type of cancer, chemotherapy, surgery, central venous catheters, pre-chemotherapy platelet and leukocyte count are associated with high risk of VTE in cancer patients. Landmark studies demonstrated that effective prophylaxis and treatment of VTE reduced morbidity and increased survival. Low-molecular-weight heparin (LMWH) is preferred as an effective and safe means for prophylaxis and treatment of VTE. It has largely replaced unfractionated heparin and vitamin K antagonists. The advantages of LMWH include increased survival and quality of life, decreased rate of VTE, low incidence of thrombocytopenia. New guidelines for prophylaxis and treatment are now available and prophylaxis is recommended in hospitalized cancer patients and patients undergoing major surgery. Treatment with LMWH should be considered as the first line of therapy for established VTE and to prevent recurrent thrombosis in patients with cancer.

Enhanced Recovery in a Minimally Invasive Thoracic Surgery Program

“…The hypercoagulability in cancer involves several complex mechanisms, including interaction among cancer cells, host cells, and the coagulation system. 44 Venous stasis is more likely to occur in surgical patients who do not ambulate after surgery because blood flow through the legs varies with activity of muscles. 37 Inactivity associated with general anesthesia, surgery, and any prolonged period of bed rest promotes venous stasis.…”

Characterization and Culture Optimization of an Glucosidase Inhibitor-producing Bacteria, Gluconobactor oxydans CK-2165

“…Based on information from Amar, 1997;Dellinger et al, 2004;De Sutter et al, 2006;Fearon et al, 2005;Gan et al, 2003;Ginsberg, 2008;Johnson & Monkhouse, 2009;Kakkar, 2009;Karimi & Cohan, 2010;Kehlet, 2008;Mangram et al, 1999;Maron & Fry, 2008;Portenoy & Lesage, 1999;Rosenquist & Rosenburg, 2003;Rosevear et al, 2006;Stock et al, 1985;Tapson, 2008;Walsh & Walsh, 2005;Weigelt, 2007. and without complications and exploratory variables of interest (demographic characteristics, emotional distress, number of comorbidities, stage of cancer, new or recurrent disease, and length of hospital stay) were tested using nonparametric Spearman rho correlations. A two-sided p value lower than 0.05 was considered statistically significant.…”

Hemostasis and cancer-associated thrombosis: modern prevention and treatment

“…В настоящее время заболеваемость рак-ассоциированным тромбозом находится на подъеме [1,[8][9][10][11], который связывают не только с распространенностью ЗНО среди населения, увеличением возраста заболевших, но и с эффективным обнаружением случайного тромба при обследовании.…”